Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-037761

CSO, Head Res.&Non-Clin. Dev. sold 48,368 shares at $24.34 ($1,177,277)

  • CSO, Head Res.&Non-Clin. Dev. acquired 48,368 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kavanaugh William Michael · CSO, Head Res.&Non-Clin. Dev.

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2017-10-04 Exercise or conversion : show line 1 in the form +48,368 $4.47 $216,340 62,285 D
2017-10-04 Sale : show line 2 in the form −48,368 $24.34 $1,177,277 13,917 D
Open-market sales · 48,368 sh · avg $24.34 · $1,177,277

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2017-10-04 Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) −48,368 48,368 D
Loading xslF345X03/doc1.xml…